Sai Life
Sai Life Q1 FY26: Capex ₹700 Cr
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Get Sai Life's next results in your feed
Guidance rank: #65 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Sai Life Sciences anticipates sustained growth driven by both existing and late-stage pipeline products with strong visibility from client demand (Page 15). Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth).
From Sai Life's Q1 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Sai Life Sciences anticipates sustained growth driven by both existing and late-stage pipeline products with strong visibility from client demand (Page 15).
- The company targets a 3-5 year CAGR around 15% across combined CRO and CDMO businesses (Page 11).
- Manufacturing capacity is expected to increase by approximately 80-90% by FY'27, supporting volume growth (Page 12, 11).
- Process R&D capacity is planned to nearly double by next year, enhancing support for clinical and commercial supply programs (Page 3, 8).
- Growth will be fueled by new modalities like oligonucleotides (near commercial), ADCs (late-phase assets), peptides (early clinical stage), and lipids (Page 9).
- No major impact is expected from reshoring or US capacity additions on intermediates and APIs supplied by Sai (Page 15).
2 more points from Sai Life's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sai Life said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sai Life Sciences is undertaking a large CAPEX of ₹700 crores for FY26.
- This CAPEX is based on strong visibility from existing products scaling up and late-stage pipeline projects plus clinical inquiries and collaborations.
- ₹700 crores CAPEX is for the current year, with CAPEX likely continuing next year though numbers are not finalized.
- The CAPEX covers manufacturing expansions including new production blocks (totaling around 450 KL capacity by H2 FY27) and Discovery capacity additions.
- Research & Development (R&D) capacity is doubling by next year, and manufacturing capacity is expected to increase by about 80%-90% by FY27.
- New capacity additions include 91 KL commissioned recently, 200 KL by Q3 FY27, and 450 KL expected by H2 FY27.
2 more points from Sai Life's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Life said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has better visibility on order book now compared to the past, with increased confidence about utilization levels going forward.
- The capacity buildup is now more aligned with anticipated orders over the next 12-24 months, indicating strong client commitments.
- Late-stage pipeline visibility is strong, supported by existing forecasts, clinical inquiries, and ongoing development programs with large pharma.
2 more points from Sai Life's call on order book
Create a free account to keep reading this call
Sai Life — Quarterly revenue & net profit
Sai Life Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 496 | 280 | +77.1% | 580 | -14.5% |
| Operating profit (EBITDA) | 121 | 26 | +365.4% | 158 | -23.4% |
| Operating margin | 24% | 9% | +15 pp | 27% | -3 pp |
| Profit before tax | 81 | -18 | — | 119 | -31.9% |
| Net profit (PAT) | 60 | -14 | — | 88 | -31.8% |
| EPS (₹) | 2.90 | — | — | 4.24 | -31.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹602 Cr, net profit ₹104 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sai Life and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sai Life Q1 FY26 results?
Sai Life Sciences anticipates sustained growth driven by both existing and late-stage pipeline products with strong visibility from client demand (Page 15). Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth).
What is Sai Life share price analysis?
Sai Life currently shows a neutral. The stock trades at a P/E of 84.1 with a market cap of ₹30,940 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Life planning capital expenditure?
Sai Life Sciences is undertaking a large CAPEX of ₹700 crores for FY26.
Keep Sai Life on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.